$AQST

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST

The Pomerantz LLP law firm has announced a class action lawsuit against Aquestive Therapeutics, Inc. (AQST) regarding alleged securities fraud or unlawful business practices. The lawsuit follows Aquestive's stock price drop after the FDA identified deficiencies in its New Drug Application for Anaphylm, delaying its approval indefinitely. Investors who purchased Aquestive securities during the Class Period have until May 4, 2026, to seek appointment as Lead Plaintiff.

Original reporting
Published Mar 25, 2026, 4:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 25, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Aquestive Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – AQST — source image
Decision brief

The 30-second read

$AQSTBearishMed
01

Why it matters

Legal and regulatory setbacks are likely to exert downward pressure in the near term, but the long-term impact depends on resolution outcomes.

02

Market read

High relevance due to recent legal action and FDA delays impacting AQST's stock and investor sentiment.

03

What to watch

Potential positive developments, such as settlement or FDA approval upon addressing deficiencies, could reverse the negative trend.

Timing: Immediate to short-term

Background

The lawsuit follows a delay in FDA approval due to deficiencies in AQST's NDA for Anaphylm, leading to a stock price decline.

Company-level read

Ticker impact

$AQSTBearishHigh confidence
Context

High relevance due to legal action and recent stock decline

Expected impact

Potential short-term decline of 5-10%

Evidence & confidence

The lawsuit and FDA issues are factual events with immediate market reactions, supported by the bearish sentiment score (-0.42). Technical indicators are not provided, but the recent stock drop suggests negative momentum.

Market effects

Potential negative impact on biotech and pharmaceutical sectors due to legal and regulatory risks

Limited regional impact; primarily affects US biotech stocks

Minimal global market effect, specific to AQST and related sectors

Counterpoint

The lawsuit may be a temporary setback; if AQST resolves the issues swiftly, the stock could rebound in the medium term.

Key entities

  • Pomerantz LLP

    Legal firm initiating class action lawsuit against AQST.

  • Aquestive Therapeutics, Inc.

    Company facing legal and regulatory challenges affecting its stock.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.